Top

Osteoporosis International

Published in:

01-04-2016 | Letter

Proton pump inhibitors and fracture: they impair bone quality and increase fall risk?

Authors: T. Sugiyama, K. Watarai, T. Oda, Y. T. Kim, H. Oda

Published in: Osteoporosis International | Issue 4/2016

Excerpt

Dear Editor, …

Zhou B, Huang Y, Li H, Sun W, Liu J (2016) Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int 27:339–347. doi:10.1007/s00198-015-3365-x CrossRefPubMed

Sugiyama T, Torio T, Miyajima T, Kim YT, Oda H (2016) Calcium, proton pump inhibitors, and fracture risk. Osteoporos Int 27:349–350. doi:10.1007/s00198-015-3403-8 CrossRefPubMed

Zhou B, Huang Y, Li H, Sun W, Liu J (2015) Proton pump inhibitors and fracture risk: response to comments. Osteoporos Int. doi:10.1007/s00198-015-3434-1 PubMedCentral

Lau AN, Tomizza M, Wong-Pack M, Papaioannou A, Adachi JD (2015) The relationship between long-term proton pump inhibitor therapy and skeletal frailty. Endocrine 49:606–610CrossRefPubMedPubMedCentral

Schoenfeld AJ, Grady D (2016) Adverse effects associated with proton pump inhibitors. JAMA Intern Med. doi:10.1001/jamainternmed.2015.7927

Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME (2016) Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. doi:10.1001/jamainternmed.2015.7193 PubMedCentral

Bucur RC, Panjwani DD, Turner L, Rader T, West SL, Jamal SA (2015) Low bone mineral density and fractures in stages 3–5 CKD: an updated systematic review and meta-analysis. Osteoporos Int 26:449–458CrossRefPubMed

Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ, Ungprasert P, O’Corragain OA, Korpaisarn S, Erickson SB (2015) Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail 37:1237–1241CrossRefPubMed

de Baaij JH, Hoenderop JG, Bindels RJ (2015) Magnesium in man: implications for health and disease. Physiol Rev 95:1–46CrossRefPubMed

10.

Uzoigwe OF (2016) Proton pump inhibitors and fracture: they do what it says on the tin? Osteoporos Int. doi:10.1007/s00198-016-3497-7

11.

Feng S, Luo Z, Liu D (2015) Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis. J Bone Miner Metab 33:448–454CrossRefPubMed

12.

Duong LT, Leung AT, Langdahl B (2015) Cathepsin K inhibition: a new mechanism for the treatment of osteoporosis. Calcif Tissue Int. doi:10.1007/s00223-015-0051-0

13.

Solomon DH, Diem SJ, Ruppert K, Lian YJ, Liu CC, Wohlfart A, Greendale GA, Finkelstein JS (2015) Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J Bone Miner Res 30:232–239CrossRefPubMedPubMedCentral

14.

Jung SB, Nagaraja V, Kapur A, Eslick GD (2015) Association between vitamin B12 deficiency and long-term use of acid-lowering agents: a systematic review and meta-analysis. Intern Med J 45:409–416CrossRefPubMed

15.

Bailey RL, van Wijngaarden JP (2015) The role of B-vitamins in bone health and disease in older adults. Curr Osteoporos Rep 13:256–261CrossRefPubMed

16.

Sugiyama T, Kim YT, Oda H (2016) Skeletal adaptation to mechanical strain: a key role in osteoporosis. In: Shimada Y, Miyakoshi N (eds) Osteoporosis in orthopedics: assessment and therapeutic options. Springer, Tokyo, pp 3–22CrossRef

17.

Sugiyama T, Torio T, Sato T, Matsumoto M, Kim YT, Oda H (2015) Improvement of skeletal fragility by teriparatide in adult osteoporosis patients: a novel mechanostat-based hypothesis for bone quality. Front Endocrinol 6:6

18.

Sugiyama T, Kono Y, Sekiguchi K, Kim YT, Oda H (2015) Age-related fragility fracture: insights from the natural homeostatic system in the skeleton. Arch Osteoporos 10:45CrossRefPubMed

19.

Saito M, Marumo K (2016) Collagen cross-links as a determinant of bone quality. In: Shimada Y, Miyakoshi N (eds) Osteoporosis in orthopedics: assessment and therapeutic options. Springer, Tokyo, pp 35–54CrossRef

20.

Thaler HW, Sterke CS, van der Cammen TJ (2016) Association of proton pump inhibitor use with recurrent falls and risk of fractures in older women: a study of medication use in older fallers. J Nutr Health Aging 20:77–81CrossRefPubMed

Title: Proton pump inhibitors and fracture: they impair bone quality and increase fall risk?
Authors: T. Sugiyama
K. Watarai
T. Oda
Y. T. Kim
H. Oda
Publication date: 01-04-2016
Publisher: Springer London
Published in: Osteoporosis International / Issue 4/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-016-3509-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Proton pump inhibitors and fracture: they impair bone quality and increase fall risk?

Excerpt

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2016

Optimal serum cholesterol concentrations are associated with accelerated bone loss in African ancestry men

Polycythemia is associated with bone loss and reduced osteoblast activity in mice

Osteoporosis in adults with cerebral palsy: feasibility of DXA screening and risk factors for low bone density

Greater serum carotenoid concentration associated with higher bone mineral density in Chinese adults

Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies

Achieving the protection of high peak bone mass